Authors suggest that Immodulon’s lead drug candidate, IMM-101, could have potential in enhancing trained immunity and so overcome one of the key obstacles to generating a safe and effective COVID-19 vaccine
Uxbridge, UK – 17th September 2020 – Immodulon, the immuno-oncology company, is pleased to announce the publication of a review article in the peer-reviewed journal, Frontiers in Immunology. The article reviews the available scientific literature on the obstacles to safe and effective COVID-19 vaccine development.
The article, “Mitigating coronavirus induced dysfunctional immunity in COVID-19: Trained immunity, BCG and ‘new old friends’”, concludes that continued studies of human and non-human primate immune response to different SARS-CoV-2 vaccines in the pipeline are required to mitigate potential adverse effects in high-risk populations around the globe, such as those patients undergoing cancer treatment. Based on the ability of certain immunomodulators to enhance ‘trained immunity’, the modification of cells in the innate immune system to create a “memory” of their activation to subsequently respond more efficiently to unrelated pathogens, the authors propose that live-attenuated Bacille Calmette-Guérin (BCG) or heat-inactivated Mycobacterium obuense (IMM-101) have the potential to address a key challenge posed by the current lack of effective prophylactic treatments and vaccines for COVID-19, in general and for high-risk populations especially.
Reference: Kleen T-O, Galdon AA, MacDonald AS and Dalgleish AG (2020) Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and “New Old Friends”. Front. Immunol. 11:2059. doi: 10.3389/fimmu.2020.02059
About Immodulon Therapeutics
Immodulon Therapeutics Limited (London, UK) is a privately-owned clinical-stage immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. It contains heat-killed whole cell Mycobacterium obuense which activates dendritic cells and other cells of the innate immune system by several mechanisms, including via Toll-like receptors. Its mechanism of action should not only make this product applicable to a range of cancers but, in combination with immune checkpoint inhibitors and other standard-of care treatments, it is expected to enhance their efficacy without increasing the safety burden for the patient. For more information about Immodulon, please visit www.immodulon.com.